Plain-English translation of NCT06749600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is collecting detailed medical information from patients who have been diagnosed with primary ovarian leiomyosarcoma (POLMS), a very rare type of ovarian cancer. Researchers will review medical records and treatment histories—both from patients treated in the past and those being treated now—to understand how this disease behaves, which treatments work best, and what the long-term outcomes are for patients.
Primary ovarian leiomyosarcoma is extremely rare, so doctors know very little about it. By gathering information from many patients across multiple hospitals, researchers hope to identify patterns in how the disease develops, which treatments are most effective, and how patients fare over time—ultimately helping doctors care for future patients better.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will review your medical records, pathology reports, and treatment history. The study collects information about your symptoms, the specifics of your cancer, what treatments you received, and how you've responded over time. There are no new procedures or visits required—participation simply means allowing the research team to access and use your existing medical information, which will be kept confidential and combined with data from other patients to identify patterns.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Italy